Male Breast Reduction in Rio de Janeiro BR
Breasts in males are called genycomastia, a Greek word meaning "breasts looking similar to women's". 40-60% of men have breasts; many conditions can cause this phenomenon like medication and medical problems (alcohol use, marihuana and steroids), but in most of the cases the reason is not known. It can damage self-confidence and self esteem, therefore breast reduction can help.
The ideal candidates for the operation are men with genicomastia for at least a year long who have developed chest muscles and elastic skin. The surgery is not recommended for overweight men who can't loose weight using diet and exercise.
In case of extra breast tissue the surgeon will remove it through an invisible cut around the nipple or below the breast fold. Sometimes extra fat also removed using this method; the canula used for suction of the fat is inserted through the cut already made. When there is extra skin needs to be removed, the procedure may leave bigger scars.
If the extra tissue is fat, liposuction is performed. The cuts, 5-7 millimeters long, are made at the margins of the breast, from below and from the side. Sometimes small cut is made around the nipple. You may feel a vibration sensation, but no pain, if the procedure is done using local anesthetics. In extreme cases when there is large amounts of fat and tissue extracted, the extra skin needs to be removed, then a drainage tube usually left to prevent fluid collection.
Finally, incisions are closed and pressure bandages are placed.
Every operation has its risks. The risks include infection, bleeding, fluid collection, breast asymmetry (that needs to be corrected in additional surgery), scars, nipple distortion and permanent color changes of the skin.
After the surgery you may feel uncomfortable, regardless of the technique used. It can be treated with painkillers. Swelling and hemorrhage may appear in the area, to reduce the swelling you'll be instructed to wear a tight bandage around the chest for several weeks day and night. The breast will reach their final size in 3 month or so. You'll be able to go back to work after a week or two. It is advised to restrain from sexual activity or physical efforts for at least 2 weeks, and any activity that may harm the chest for a month. It's important to avoid sunlight to your chest for 6 month to prevent color changes in the breast.
More Rio de Janeiro info...
Rio de Janeiro By bus
The long-distance bus depot, Rodovi?ria Novo Rio, is located in the North Zone's Santo Cristo neighborhood. Taxis and coach buses can get you to the South Zone in about fifteen minutes; local buses take a bit longer. Fresc?o air-conditioned coaches can be caught just off the bus station. The coaches connect the station to the city center and main hotel areas of Copacabana and Ipanema. Bus companies include :
-
Rio de Janeiro By car
Traffic within some parts of Rio can be daunting, but a car may be the best way to reach distant beaches like Grumari, and that can be an extra adventure. Avoid rush-hour traffic jams in neighborhoods such as Copacabana, Botafogo, Laranjeiras, and Tijuca, where moms line up their cars to pick up their children after school. In Rio, most road signals are placed after the curve you were supposed to take, and do not help unless you already know how to go there. Buy a map, and have fun.
-
Male Breast ReductionLatest Forum Posts...
- hi, are there any non-surgical procedures that can be done to reduce my man-breasts? it's kinda annoying and embarrassing.
Plastic Surgery News...
Context Individuals with diabetes are at increased risk for cardiovascular disease (CVD), but more aggressive targets for risk factor control have not been tested.
Objective To compare progression of subclinical atherosclerosis in adults with type 2 diabetes treated to reach aggressive targets of low-density lipoprotein cholesterol (LDL-C) of 70 mg/dL or lower and systolic blood pressure (SBP) of 115 mm Hg or lower vs standard targets of LDL-C of 100 mg/dL or lower and SBP of 130 mm Hg or lower.
Design, Setting, and Participants A randomized, open-label, blinded-to-end point, 3-year trial from April 2003-July 2007 at 4 clinical centers in Oklahoma, Arizona, and South Dakota. Participants were 499 American Indian men and women aged 40 years or older with type 2 diabetes and no prior CVD events.
Interventions Participants were randomized to aggressive (n=252) vs standard (n=247) treatment groups with stepped treatment algorithms defined for both.
Main Outcome Measures Primary end point was progression of atherosclerosis measured by common carotid artery intimal medial thickness (IMT). Secondary end points were other carotid and cardiac ultrasonographic measures and clinical events.
Results Mean target LDL-C and SBP levels for both groups were reached and maintained. Mean (95% confidence interval) levels for LDL-C in the last 12 months were 72 (69-75) and 104 (101-106) mg/dL and SBP levels were 117 (115-118) and 129 (128-130) mm Hg in the aggressive vs standard groups, respectively. Compared with baseline, IMT regressed in the aggressive group and progressed in the standard group (–0.012 mm vs 0.038 mm; P < .001); carotid arterial cross-sectional area also regressed (–0.02 mm2 vs 1.05 mm2; P < .001); and there was greater decrease in left ventricular mass index (–2.4 g/m2.7 vs –1.2 g/m2.7; P = .03) in the aggressive group. Rates of adverse events (38.5% and 26.7%; P = .005) and serious adverse events (n = 4 vs 1; P = .18) related to blood pressure medications were higher in the aggressive group. Clinical CVD events (1.6/100 and 1.5/100 person-years; P = .87) did not differ significantly between groups.
Conclusions Reducing LDL-C and SBP to lower targets resulted in regression of carotid IMT and greater decrease in left ventricular mass in individuals with type 2 diabetes. Clinical events were lower than expected and did not differ significantly between groups. Further follow-up is needed to determine whether these improvements will result in lower long-term CVD event rates and costs and favorable risk-benefit outcomes.
Trial Registration clinicaltrials.gov Identifier: NCT00047424
- "How Non-Group Health Coverage Varies With Income," Kaiser Family Foundation: The analysis examines how often people at different income levels purchase individual health coverage when they do not have access to employer-sponsored coverage or do not obtain public coverage. Researchers found that relatively few people at lower incomes buy individual coverage.